Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Clinical trial NCT06555796 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06555796
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Prostate Cancer High-risk Biochemical Recurrence High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer Non-metastatic Castration-sensitive Prostate Cancer

Start date: 2024-09-23
Primary completion: 2026-10-08
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.